An Observational Study on The Correlation Between Time of Initiation of Avastin (Bevacizumab) Treatment And Progression-Free Survival in Patients With Metastatic Breast Cancer (CRONOS 2)

Hoffmann-La Roche83 enrolled

Overview

This single arm, prospective, observational study will assess the correlation between the time from start of chemotherapy to the start of Avastin (bevacizumab) treatment with progression-free survival in patients with previously untreated metastatic breast cancer. Patients will be followed for up to 12 months after progressive disease occurs.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Breast Cancer

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Adult patients, \>/=18 years of age * Previously untreated metastatic breast cancer * Scheduled to start 1st line chemotherapeutic treatment * ECOG performance status 0-1 Exclusion Criteria: * Any conditions included in contraindication list for Avastin * Prior chemotherapy for metastatic breast cancer * Adjuvant/neoadjuvant chemotherapy or radio-chemotherapy of non-metastatic malignancy completed \<6 months prior to treatment start

Locations (1)

Unnamed facility

Cluj-Napoca, Romania

Outcomes

Primary Outcomes

Correlation between the time from start of chemotherapy to the start of Avastin treatment with progression-free survival

Time frame: 60 months

Secondary Outcomes

Overall survival

Time frame: 60 months

Safety: Incidence of adverse events

Time frame: 60 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.